Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy targets Hard-to-Treat cancers in first human trial

NCT ID NCT07613723

Recruiting now Disease control Sponsor: Zelluna Immunotherapy AS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system attack tumors. The main goals are to check safety and find the best dose. Only 9 participants will be enrolled initially.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms non-small cell squamous lung carcinoma ovarian cancer synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER OVARIAN CANCER SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) SYNOVIAL SARCOMAS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    NOT_YET_RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.